GSK-RTG114873

Study Sponsor: GSK

Study Title

A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults with Partial Onset Seizures (Extension of Study RTG114855)

Medicine or Vaccine (generic name)

retigabine, ezogabine

Sponsor Identification Number

RTG114873

Trial Registry Identification Number(#'s)

NCT01777139

Medical Condition

Epilepsy

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=114873

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT01777139

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This is a follow-up study to RTG114855. An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.

Date Added to this Site

January 2020